{"id":10195,"date":"2026-06-20T16:47:44","date_gmt":"2026-06-20T21:47:44","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10195"},"modified":"2026-06-20T16:54:22","modified_gmt":"2026-06-20T21:54:22","slug":"nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","title":{"rendered":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

SAN DIEGO, CA,\u00a0 June 22, 2026<\/span><\/b>\u00a0\u2014\u00a0Nanoscope\u00a0Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that\u00a0Co-founder and\u00a0CEO Sulagna Bhattacharya will participate in\u00a0executive leadership\u00a0panel discussion hosted by Women\u00a0In\u00a0Bio\u00a0during the 2026 BIO International Convention.<\/span>\u00a0<\/span><\/p>

Members of the\u00a0Nanoscope\u00a0leadership team will also\u00a0attend the\u00a0BIO\u00a0International Convention\u00a0and\u00a0be\u00a0available\u00a0for meeting\u00a0at the San Diego Convention Center\u00a0during\u00a0June 22<\/span>Dakota del Norte<\/span>-25<\/span>th<\/span>.\u00a0\u00a0<\/span>\u00a0<\/span><\/p>

Panel\u00a0DETAILS<\/span><\/b>\u00a0<\/span><\/p>

Panel\u00a0Session Title:\u00a0<\/span><\/b>Building Resilient Organizations in an Era of Uncertainty<\/span>
<\/span>Fecha:\u00a0<\/span><\/b>Tuesday, June 23, 2026<\/span>\u00a0
<\/span>Tiempo:\u00a0\u00a0<\/span><\/b>5:30 \u2013 7:30 p.m. PT<\/span>\u00a0
<\/span>Ubicaci\u00f3n:\u00a0\u00a0<\/span><\/b>GENESIS Labs, 1155 Island Avenue, San Diego, CA<\/span>\u00a0
<\/span>Audience:\u00a0<\/span><\/b>Executive Leadership \u2013 Public Event<\/span>\u00a0<\/span><\/p>

PANEL PARTICIPANTS:<\/span><\/b><\/p>

SPEAKERS:
Sulagna Bhattacharya,<\/span><\/b>\u00a0CEO,\u00a0Nanoscope\u00a0Therapeutics<\/span>\u00a0
<\/span>Tamar Grossman,<\/span><\/b>\u00a0CEO, La Jolla Labs<\/span>
Erin O\u2019Donnell<\/strong>, Partner at PwC<\/span><\/p>

MODERATOR:
Katherine Andersen \u2013 <\/strong>Head of Life Science & Healthcare, HSBC Innovation Banking
<\/strong><\/p>

The\u00a0panel,\u00a0part\u00a0of\u00a0Women in Bio\u2019s (WIB) Annual Plenary during the 2026 BIO International Convention, will\u00a0bring together\u00a0female CEOs and senior leaders who have navigated complexity across science,\u00a0capital\u00a0and organizational transformation.\u00a0\u00a0Designed for executive leadership audiences, the panel will address the most pressing challenges facing leaders today: making high-stakes decisions with incomplete information,\u00a0maintaining\u00a0team alignment and culture under pressure, and building organizations that can withstand sustained change.\u00a0\u00a0The discussion will focus on leading through ambiguity, balancing transparency with confidence, managing risk, sustaining culture under pressure, and helping teams adapt\u00a0to unpredictable environments.<\/span>\u00a0<\/span><\/p>

\u201cI am honored to join this distinguished group of leaders at BIO 2026,\u201d\u00a0<\/span><\/i>said Sulagna Bhattacharya, Co-founder and CEO of\u00a0Nanoscope.<\/span>\u00a0\u201cBuilding a resilient organization is\u00a0inseparable from our mission to restore vision\u00a0for patients living\u00a0with\u00a0retinal degeneration.\u00a0\u00a0We must lead with clarity and purpose \u2014 especially when the path forward is uncertain.\u201d<\/span><\/i>\u00a0<\/span>\u00a0<\/span><\/p>

Designed for executive leaders, the panel will offer practical perspectives and firsthand experiences for building organizations capable of not only withstanding\u00a0uncertainty but\u00a0emerging\u00a0from it stronger and better positioned to fulfill their missions.<\/span>\u00a0<\/span><\/p>

ABOUT NANOSCOPE THERAPEUTICS<\/span><\/b>\u00a0<\/span><\/p>

Nanoscope\u00a0Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b\/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (<\/span>NCT04945772<\/span><\/a>), a rolling BLA submission to the FDA has been\u00a0initiated. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in SD (<\/span>NCT05417126<\/span><\/a>) and plans to\u00a0initiate\u00a0a\u00a0<\/span>Ensayo de registro de fase 3<\/span><\/a>\u00a0in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT\u00a0designation\u00a0for SD, and EMA Orphan designations to cover non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies.\u00a0MCO-010 has received Sakigake and orphan designations for inherited retinal dystrophies (IRDs) in Japan and an orphan designation for IRDs in Saudi Arabia.\u00a0A Phase 2 program for MCO in GA\u00a0is expected\u00a0to start in 2026. Other IND-ready programs include Leber congenital amaurosis (LCA).<\/span>\u00a0<\/span><\/p>

\u00a0<\/span><\/p>

MEDIA CONTACT<\/span><\/b>\u00a0
<\/span>Nanoscope\u00a0Therapeutics, Inc.<\/span><\/b>\u00a0
<\/span>+1 (817) 857-1186<\/span>\u00a0
<\/span>PR@nanostherapeutics.com<\/span><\/a>\u00a0<\/span><\/p>

\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

SAN DIEGO, CA,\u00a0 June 22, 2026\u00a0\u2014\u00a0Nanoscope\u00a0Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that\u00a0Co-founder and\u00a0CEO Sulagna Bhattacharya will participate in\u00a0executive leadership\u00a0panel discussion hosted by Women\u00a0In\u00a0Bio\u00a0during the 2026 BIO International Convention.\u00a0 Members of the\u00a0Nanoscope\u00a0leadership team will also\u00a0attend […]<\/p>\n","protected":false},"author":1,"featured_media":10196,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-20T21:47:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-20T21:54:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel\",\"datePublished\":\"2026-06-20T21:47:44+00:00\",\"dateModified\":\"2026-06-20T21:54:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\"},\"wordCount\":537,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\",\"name\":\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"datePublished\":\"2026-06-20T21:47:44+00:00\",\"dateModified\":\"2026-06-20T21:54:22+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-06-20T21:47:44+00:00","article_modified_time":"2026-06-20T21:54:22+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel","datePublished":"2026-06-20T21:47:44+00:00","dateModified":"2026-06-20T21:54:22+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/"},"wordCount":537,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","url":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","name":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","datePublished":"2026-06-20T21:47:44+00:00","dateModified":"2026-06-20T21:54:22+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10195"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10195\/revisions"}],"predecessor-version":[{"id":10200,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10195\/revisions\/10200"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10196"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}